MedTrace Logo

Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years

NCT00161785 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2015-05-21

No results posted yet for this study

Summary

The purpose of this study is to assess:

* TBE antibody persistence 2 and 3 years after the third TBE vaccination with FSME-IMMUN 0.5ml by means of ELISA and neutralization test (NT).
* TBE antibody response to a booster vaccination with FSME-IMMUN 0.5ml, by means of ELISA and NT.

Conditions

  • Tick-borne Encephalitis

Interventions

BIOLOGICAL

FSME-IMMUN 0.5ml

Sponsors & Collaborators

Principal Investigators

  • Ryszard Konior, MD · Szpital Jana Pawla II Oddzial Neuroinfekcji, Krakow, Poland

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
67 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-06-30
Completion
2005-07-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00161785 on ClinicalTrials.gov